These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 22128223

  • 1. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
    Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F.
    Circulation; 2012 Jan 17; 125(2):271-9. PubMed ID: 22128223
    [Abstract] [Full Text] [Related]

  • 2. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F.
    Circ Heart Fail; 2014 Jan 17; 7(1):51-8. PubMed ID: 24297687
    [Abstract] [Full Text] [Related]

  • 3. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 4. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
    N Engl J Med; 2003 Apr 03; 348(14):1309-21. PubMed ID: 12668699
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators.
    J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881
    [Abstract] [Full Text] [Related]

  • 6. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F.
    Circulation; 2009 May 12; 119(18):2471-9. PubMed ID: 19398668
    [Abstract] [Full Text] [Related]

  • 7. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Olivier A, Girerd N, Michel JB, Ketelslegers JM, Fay R, Vincent J, Bramlage P, Pitt B, Zannad F, Rossignol P, EPHESUS Investigators.
    Int J Cardiol; 2017 Aug 15; 241():344-350. PubMed ID: 28284500
    [Abstract] [Full Text] [Related]

  • 8. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F.
    J Am Coll Cardiol; 2011 Nov 01; 58(19):1958-66. PubMed ID: 22032706
    [Abstract] [Full Text] [Related]

  • 9. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
    Ferreira JP, Duarte K, McMurray JJV, Pitt B, van Veldhuisen DJ, Vincent J, Ahmad T, Tromp J, Rossignol P, Zannad F.
    Circ Heart Fail; 2018 Jul 01; 11(7):e004926. PubMed ID: 29997240
    [Abstract] [Full Text] [Related]

  • 10. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, Ahmed A, Pitt B, Zannad F.
    Arch Cardiovasc Dis; 2014 Mar 01; 107(3):149-57. PubMed ID: 24630753
    [Abstract] [Full Text] [Related]

  • 11. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J, Ertl G.
    Med Klin (Munich); 2006 Jun 15; 101(6):458-66. PubMed ID: 16767569
    [Abstract] [Full Text] [Related]

  • 12. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr 15; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 13. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
    Health Technol Assess; 2010 May 15; 14(24):1-162. PubMed ID: 20492762
    [Abstract] [Full Text] [Related]

  • 14. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J.
    Cardiovasc Drugs Ther; 2001 Jan 15; 15(1):79-87. PubMed ID: 11504167
    [No Abstract] [Full Text] [Related]

  • 15. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival (EPHESUS) Investigators.
    Am Heart J; 2009 Sep 15; 158(3):437-43. PubMed ID: 19699868
    [Abstract] [Full Text] [Related]

  • 16. Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
    Keating GM, Plosker GL.
    Drugs; 2004 Sep 15; 64(23):2689-707. PubMed ID: 15537370
    [Abstract] [Full Text] [Related]

  • 17. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F, EPHESUS Investigators.
    Eur J Heart Fail; 2009 Nov 15; 11(11):1099-105. PubMed ID: 19875410
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G, Solesse A, Beillat M.
    Arch Cardiovasc Dis; 2008 Sep 15; 101(9):515-21. PubMed ID: 19041835
    [Abstract] [Full Text] [Related]

  • 19. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ, Howard PA.
    Ann Pharmacother; 2005 Jan 15; 39(1):68-76. PubMed ID: 15590870
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010 Jan 15; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.